TABLE 1.

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY POPULATION (CELEG)

	Patients with ALI		Patients with Sepsis		Healthy Control Subjects
	EA	AA	EA	AA	EA	AA
N	92	43	99	51	85	61
Sex (M/F)	55/37	24/19	59/40	33/18	41/44	25/36
Age	53.1 ± 16.6	47.9 ± 17.0	60.7 ± 19.2	58.1 ± 15.8	32.8 ± 10.5†	35.0 ± 10.8†
APACHE II	24.8 ± 7.7	25.2 ± 7.8	22.1 ± 8.6	25.7 ± 7.3	N.A.	N.A.
Survival, %	58.3†	59.1*	74.7	73.7	100	100
Cancer, %	19.7	4.5	28.0	15.8	N.A.	N.A.
CLD, %	18.0	4.8	10.7	0	N.A.	N.A.
ESRF, %	13.1	4.5	12.0	15.8	N.A.	N.A.
COPD, %	8.2	9.1	16.2	10.5	N.A.	N.A.
Alcoholism, %	14.8	28.6	9.3	16.7	N.A.	N.A.
Diabetes, %	21.3	13.6	16	36.8	N.A.	N.A.
CHF, %	6.6	4.5	14.9	21.1	N.A.	N.A.
HIV, %	0	27.3	1.3	5.3	N.A.	N.A.
AIDS, %	0	18.2	0	5.3	N.A.	N.A.
Anemia, %	19.7	22.7	23.0	52.6	N.A.	N.A.
Insult
Lung, %	61	78.3	43.8	50	N.A.	N.A.
Abdomen, %	8.5	0	15.1	16.7	N.A.	N.A.
UTI, %	5.1	0	16.4	22.2	N.A.	N.A.
Bloodstream, %	5.1	4.3	8.2	5.6	N.A.	N.A.
Other, %	20.3	17.4	16.4	5.6	N.A.	N.A.

Definition of abbreviations: ALI, acute lung injury; APACHE II, Acute Physiology and Chronic Health Evaluation; CELEG, Consortium to Evaluate Lung Edema Genetics; CHF, congestive heart failure; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; ESRF, end stage renal failure; N.A., not applicable; UTI = urinary tract infection.

Total cohort = 431 subjects, all sepsis subjects enrolled are either severe sepsis or septic shock. Age and APACHE II data expressed as mean ± SD. Survival is defined as survival to hospital discharge, measured up to 60 d. Ages and APACHE II are not significantly different between racial groups within a diagnosis.

^*P = 0.044 for survival difference ALI versus sepsis group.

^†Age of controls different versus all other groups.